Scrutiny Over Funding Model Weighs on IperionX Shares

IperionX faces legal probes over an accounting error, while institutional investors stay focused on its DoD-backed titanium production targets and $65.8M cash position.

The financing mechanisms underpinning IperionX are drawing heightened scrutiny from the investment community and legal experts. An accounting error in the company's half-year report has triggered formal investigations, raising broader questions about how the U.S. Department of Defense (DoD) is funding the firm's titanium production initiatives.

Institutional Activity Amid Legal Probes

Despite the emerging legal challenges, institutional investors have remained engaged with IperionX. Recent regulatory filings indicate that JPMorgan Chase and the Tennessee Department of Treasury have either adjusted or established new positions in the stock. A key driver for this continued interest appears to be the company's target to achieve an annual titanium production capacity of 1,400 tons by 2027.

This institutional activity unfolds against a backdrop of legal examination. Following a significant share price decline in mid-March, the law firms Bronstein, Gewirtz & Grossman and Holzer & Holzer have initiated inquiries. They are assessing whether IperionX may have violated U.S. securities laws. The equity currently trades approximately 50% below its level from 30 days prior.

The DoD Reimbursement Framework

Central to the situation is IperionX's unique funding relationship with the U.S. Department of Defense. The company operates on a reimbursement model: it initially covers project expenses from its own funds and is subsequently repaid by the DoD. As of December 31, 2025, IperionX was awaiting reimbursement for approximately $6.6 million. Furthermore, an additional $46.5 million from existing funding agreements remains untapped. This capital is earmarked for expanding titanium production at the Virginia Titanium Manufacturing Campus.

A critical nuance of this structure concerns asset ownership. Machinery and equipment procured by IperionX under these DoD contracts are legally owned by the U.S. government. The company acts merely as a procurement agent. Consequently, these assets do not appear on IperionX's balance sheet as property but as receivables. It was precisely this distinction that led to the half-year reporting error, requiring a correction that reduced the book value of usage rights from $21.4 million to $3.7 million.

Analyst Outlook and Future Milestones

Market analysts maintain a predominantly optimistic stance, though their price targets reflect a wide range of uncertainty stemming from the ongoing probes. Targets span from $52 to $71 per share. A stabilizing factor frequently cited is the company's cash position of $65.8 million.

Looking ahead, a key milestone is expected in the second quarter of 2026 with the completion of the Definitive Feasibility Study for the Titan Critical Minerals Project in Tennessee. This report is anticipated to provide greater clarity on the long-term production strategy and the project's commercial viability.